Homeopathic drug Influenzinum recalled for manufacturing process deviations
Washington Homeopathic Products is recalling Influenzinum in multiple potencies due to manufacturing process deviations. The recall affects approximately 6,400 units distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a voluntary, precautionary recall of a Class II drug with no reported illnesses or injuries. The recall was triggered by manufacturing process deviations, not a specific product hazard or contamination.
Plain-English summary
Washington Homeopathic Products, Inc. is recalling Influenzinum, a homeopathic remedy, available in potencies of 9X, 10X, 12X, 15X, 25X, 30X, 200C, 12C, 30C, and 1M in both liquid and pellet formulations. Approximately 6,406 glass amber bottles were distributed nationwide.
The company initiated this voluntary recall on May 13, 2022, due to deviations from current good manufacturing practices (cGMP). The affected lot numbers are 28960, 28962, 28961, 27415, and 27464.
Consumers who have purchased Influenzinum in the affected lots should discontinue use of the product.
The recalled product
- Product
- Influenzinum, Potency: 9X, 10X, 12X, 15X, 25X, 30X, 200C, 12C, 30C 1M, Liquid Pellets, OTC, Washington Homeopathic Products, 260 JR Hawvermale Way, Berkeley Springs, WV 25411
- Manufacturer
- Washington Homeopathic Products, Inc.
- Category
- Drug — Homeopathic / OTC
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot # 28960
- 28962
- 28961
- 27415
- 27464
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27